Facial onset sensory and motor neuronopathy

What causes facial onset sensory and motor neuronopathy?

The underlying cause of facial onset sensory and motor neuronopathy (FOSMN) is currently unknown. Because the clinical features and severity of the condition can vary significantly from person to person, it is thought that there may be a multifactorial cause. Some studies suggest that the condition may occur due to an abnormal immune response or neurodegeneration (degeneration of certain motor and sensory neurons, specifically).

Studies have also shown that SOD1 and OPMD genes may play a role in FOSMN; however, the specific association is unclear. Although there are currently no familial cases of FOSMN reported in the medical literature, some scientists suspect that newer genetic testing technologies may uncover additional genetic factors.

Last updated on 05-01-20

How is facial onset sensory and motor neuronopathy diagnosed?

Due to the small number of reported cases, there are no agreed upon diagnostic criteria for facial onset sensory and motor neuronopathy. A diagnosis is often suspected based on the presence of characteristic signs and symptoms. Additional tests may then be ordered to support the diagnosis and rule out other conditions that are associated with similar features. These include:

Last updated on 05-01-20

Is facial onset sensory and motor neuronopathy inherited?

There is currently no evidence to suggest that facial onset sensory and motor neuronopathy is inherited. To date, no familial cases have been reported which means that the condition appears to occur sporadically in people with no family history of the condition.

Last updated on 05-01-20

How might facial onset sensory and motor neuronopathy be treated?

Due to the rarity of the condition, the best approach for effective treatment is currently unclear. Several treatments have been mentioned in case reports including intravenous immunoglobulin (IVIG), plasmapheresis (PE), corticosteroids, azathioprine, mycophenolate mofetil, and rituximab. Although some patients showed temporary improvements with IVIG and PE, the majority of cases did not respond to any of these treatments.

Last updated on 05-01-20

Name: FOSMN Patients Foundation Email: https://fosmn.org/contact/ Url: https://fosmn.org/

Connect with other users with Facial onset sensory and motor neuronopathy on the RareGuru app

Do you have information about a disease, disorder, or syndrome? Want to suggest a symptom?
Please send suggestions to RareGuru!

The RareGuru disease database is regularly updated using data generously provided by GARD, the United States Genetic and Rare Disease Information Center.

People Using the App

Join the RareGuru Community

To connect, share, empower and heal today.

People Using the App